Compositions and methods for treating retinal diseases
Henry Klassen, Irvine, CA (US); and Jing Yang, Irvine, CA (US)
Assigned to The Regents of the University of California, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Aug. 6, 2020, as Appl. No. 16/987,183.
Application 15/144,628 is a division of application No. 14/715,464, filed on May 18, 2015, granted, now 10,041,041, issued on Aug. 7, 2018.
Application 14/715,464 is a division of application No. 14/118,223, granted, now 9,107,897, issued on Aug. 18, 2015, previously published as PCT/US2012/038342, filed on May 18, 2012.
Application 16/987,183 is a continuation of application No. 16/909,908, filed on Jun. 23, 2020, granted, now 10,781,422.
Application 16/909,908 is a continuation of application No. 16/743,930, filed on Jan. 15, 2020, granted, now 10,822,585.
Application 16/743,930 is a continuation of application No. 15/951,955, filed on Apr. 12, 2018, granted, now 10,752,882.
Application 15/951,955 is a continuation of application No. 15/144,628, filed on May 2, 2016, granted, now 9,963,675, issued on May 8, 2018.
Claims priority of provisional application 61/487,419, filed on May 18, 2011.
Prior Publication US 2021/0189333 A1, Jun. 24, 2021
1. A cell population comprising mammalian retinal progenitor cells, wherein the mammalian retinal progenitor cells express one or more markers selected from the group consisting of nestin, Sox2, Ki-67, MHC Class I, and Fas/CD95, wherein nestin is expressed by greater than 90% of the cells in the population, wherein Sox2 is expressed by greater than 80% of the cells in the population, wherein Ki-67 is expressed by % greater than 30% of the cells in the population, wherein MHC Class I is expressed by greater than 70% of the cells in the population, and wherein Fas/CD95 is expressed by greater than 30% of the cells in the population.